| Title | Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir. |
| Publication Type | Journal Article |
| Year of Publication | 2012 |
| Authors | Edelman, Jennifer E., Kirsha Gordon, Maria C. Rodriguez-Barradas, and Amy C. Justice |
| Corporate Authors | VACS Project Team |
| Journal | AIDS patient care and STDs |
| Volume | 26 |
| Issue | 6 |
| Pagination | 312-9 |
| Date Published | 2012 Jun |
| ISSN | 1557-7449 |
| Keywords | Adenine, Anti-HIV Agents, Benzoxazines, Cohort Studies, Cross-Sectional Studies, Deoxycytidine, Drug Therapy, Combination, Female, Health Status, HIV Infections, Humans, Male, Middle Aged, Organophosphonates, Quality of Life, Severity of Illness Index, Treatment Outcome, Veterans |
| Abstract | Most patients (80-90%) newly diagnosed with HIV are started on the antiretroviral regimen efavirenz, emtricitabine, and tenofovir (EFV/FTC/TDF). Existing studies of patient tolerability, however, are limited. We compared symptom experiences of patients on EFV/FTC/TDF, and the subsequent impact on health-related quality of life, with those of patients on other combination antiretroviral therapy (cART). We conducted a cross-sectional analysis of the Veterans Aging Cohort Study from February 2008 to August 2009 to compare the symptom experiences of patients on EFV/FTC/TDF vs. other cART, unadjusted and then adjusted for treatment characteristics, and comorbid disease severity. We then assessed the association between EFV/FTC/TDF use and health-related quality of life. Among the 1,759 patients in our analytic sample, EFV/FTC/TDF use was associated with fewer symptoms than was other cART. The use of EFV/FTC/TDF was independently associated with health-related quality of life, and this association was at least partially explained by symptom burden. |
| DOI | 10.1097/QAI.0b013e3181fbc94f |
| Alternate Journal | AIDS Patient Care STDS |
